Literature DB >> 19061720

Clinical correlates, heritability, and genetic linkage of circulating CD40 ligand in the Framingham Offspring Study.

John F Keaney1, Izabella Lipinska, Martin G Larson, Josée Dupuis, Jane E Freedman, Naomi M Hamburg, Joseph M Massaro, Jian Rong, Patrice Sutherland, Joseph A Vita, Ramachandran S Vasan, Emelia J Benjamin.   

Abstract

BACKGROUND: The CD40 receptor and its ligand (CD40L) are known to modulate both inflammation and thrombosis-2 processes important for the development and clinical expression of atherosclerosis. Circulating soluble CD40L (sCD40L) concentration predicts cardiovascular risk in selected patient samples. The purpose of this study was to determine the predictors of sCD40L in a large, community-based sample.
METHODS: We determined both serum and plasma sCD40L concentration in 3,259 participants (54% women) from the Framingham Offspring Study.
RESULTS: In multivariable models, advancing age was the only consistent (inverse) correlate of both serum and plasma sCD40L concentration. Overall, the variability explained by clinical covariates was very low for both measurements of sCD40L; with values of only 1.4% and 2.7% for serum and plasma, respectively. We observed that genetic factors accounted for a modest (12% serum; 14% plasma) amount of the adjusted variability in sCD40L.
CONCLUSIONS: Circulating sCD40L concentration was poorly associated with known cardiovascular disease (CVD) risk factors and was modestly heritable. Determining if either serum or plasma sCD40L are predictive of CVD risk in the community will require longitudinal follow-up.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19061720      PMCID: PMC2613323          DOI: 10.1016/j.ahj.2008.06.041

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  36 in total

1.  Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells.

Authors:  Uwe Schönbeck; Norbert Gerdes; Nerea Varo; Rebecca S Reynolds; Daniel B Horton; Udo Bavendiek; Linda Robbie; Peter Ganz; Scott Kinlay; Peter Libby
Journal:  Circulation       Date:  2002-12-03       Impact factor: 29.690

2.  Endothelial function: a barometer for cardiovascular risk?

Authors:  Joseph A Vita; John F Keaney
Journal:  Circulation       Date:  2002-08-06       Impact factor: 29.690

3.  Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease.

Authors:  Nikolaus Marx; Armin Imhof; Johannes Froehlich; Laila Siam; Jochen Ittner; Gerhard Wierse; Arnold Schmidt; Winfried Maerz; Vinzenz Hombach; Wolfgang Koenig
Journal:  Circulation       Date:  2003-04-14       Impact factor: 29.690

4.  Requirement for CD154 in the progression of atherosclerosis.

Authors:  E Lutgens; L Gorelik; M J Daemen; E D de Muinck; I S Grewal; V E Koteliansky; R A Flavell
Journal:  Nat Med       Date:  1999-11       Impact factor: 53.440

5.  Soluble CD40L and cardiovascular risk in women.

Authors:  U Schönbeck; N Varo; P Libby; J Buring; P M Ridker
Journal:  Circulation       Date:  2001-11-06       Impact factor: 29.690

6.  Mutations of CD40 gene cause an autosomal recessive form of immunodeficiency with hyper IgM.

Authors:  S Ferrari; S Giliani; A Insalaco; A Al-Ghonaium; A R Soresina; M Loubser; M A Avanzini; M Marconi; R Badolato; A G Ugazio; Y Levy; N Catalan; A Durandy; A Tbakhi; L D Notarangelo; A Plebani
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-23       Impact factor: 11.205

7.  Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia.

Authors:  C D Garlichs; S John; A Schmeisser; S Eskafi; C Stumpf; M Karl; M Goppelt-Struebe; R Schmieder; W G Daniel
Journal:  Circulation       Date:  2001-11-13       Impact factor: 29.690

Review 8.  Inflammation and atherosclerosis.

Authors:  Peter Libby; Paul M Ridker; Attilio Maseri
Journal:  Circulation       Date:  2002-03-05       Impact factor: 29.690

9.  Soluble CD40 ligand in acute coronary syndromes.

Authors:  Christopher Heeschen; Stefanie Dimmeler; Christian W Hamm; Marcel J van den Brand; Eric Boersma; Andreas M Zeiher; Maarten L Simoons
Journal:  N Engl J Med       Date:  2003-03-20       Impact factor: 91.245

10.  Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy.

Authors:  Anne G Semb; Sanne van Wissen; Thor Ueland; Tineke Smilde; Torgun Waehre; Mieke D Tripp; Stig S Frøland; John J P Kastelein; Lars Gullestad; Terje R Pedersen; Pål Aukrust; Anton F H Stalenhoef
Journal:  J Am Coll Cardiol       Date:  2003-01-15       Impact factor: 24.094

View more
  3 in total

Review 1.  Emerging inflammatory markers for assessing coronary heart disease risk.

Authors:  Marshall A Corson
Journal:  Curr Cardiol Rep       Date:  2009-11       Impact factor: 2.931

2.  Effects of cranberry juice consumption on vascular function in patients with coronary artery disease.

Authors:  Mustali M Dohadwala; Monika Holbrook; Naomi M Hamburg; Sherene M Shenouda; William B Chung; Megan Titas; Matthew A Kluge; Na Wang; Joseph Palmisano; Paul E Milbury; Jeffrey B Blumberg; Joseph A Vita
Journal:  Am J Clin Nutr       Date:  2011-03-16       Impact factor: 7.045

3.  Effects of Concord grape juice on ambulatory blood pressure in prehypertension and stage 1 hypertension.

Authors:  Mustali M Dohadwala; Naomi M Hamburg; Monika Holbrook; Brian H Kim; Mai-Ann Duess; Aaron Levit; Megan Titas; William B Chung; Felix B Vincent; Tara L Caiano; Alissa A Frame; John F Keaney; Joseph A Vita
Journal:  Am J Clin Nutr       Date:  2010-09-15       Impact factor: 7.045

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.